Predictors of Durable Hepatitis B Surface Antigen Loss After Pegylated Interferon–Based Therapy in Patients with Hepatitis B e Antigen–Negative Chronic Hepatitis B: A Multicenter Real-World Study
The Journal of Infectious Diseases · 2025
DOI: 10.1093/infdis/jiaf198 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Jun Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Interferon-alpha, Hepatitis B Surface Antigens, Antiviral Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hunan Province, Key Research and Development Program of Hunan Province.
Abstract (Originalsprache)
Background
Hepatitis B surface antigen (HBsAg) loss is durable in some patients with chronic hepatitis B (CHB) after pegylated interferon α (Peg-IFNα)–based treatment. However, factors associated with durable HBsAg loss are not clear. This study aimed to investigate predictors of durable HBsAg loss.
Methods
Patients with CHB and HBsAg loss were enrolled from 2018 to 2022 in the Everest Project and followed up for 48 weeks after Peg-IFNα therapy discontinuation. Sustained response (SR) was defined as durable HBsAg loss with or without hepatitis B surface antibody (HBsAb) appearance at the end of follow-up, while recurrence was characterized by HBsAg reversal and/or detectable HBV DNA during follow-up. Data on the risk factors of durable HBsAg loss were analyzed between SR and recurrence.
Results
A total of 1046 patients were included in this study: 822 with SR and 224 with recurrence. At end of follow-up, 1.41% (224/1046) had relapsed. HBsAb at the end of Peg-IFNα treatment and Peg-IFNα consolidation therapy time were associated with SR (area under the receiver operating curve [AUROC], 0.709 [P < .001]; AUROC, 0.620 [P < .001], respectively), with the optimal cutoff values of 25.67 IU/L and 12.786 weeks. The prediction model was based on HBsAb at end of treatment and consolidation therapy time, and AUROCs of the model for predicting efficacy in the training and validation sets were 0.7071 and 0.736.
Conclusions
HBsAb at end of treatment and Peg-IFNα consolidation therapy time are potential predictors of durable HBsAg loss.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases.
- Key Laboratory of Viral Hepatitis of Hunan Province.
- National Clinical Research Center for Geriatric Disorders.
- Department of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha.
- Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
ORCID-Profile: Yongwen Yang, Yan Huang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Hunan Province
- Key Research and Development Program of Hunan Province
Zitieren
APA
Chen, J., Huang, Z., Yang, X., Yang, Y., Tan, M., Duan, L., Li, X., Gao, S., Gao, Z., & Huang, Y. (2025). Predictors of Durable Hepatitis B Surface Antigen Loss After Pegylated Interferon–Based Therapy in Patients with Hepatitis B e Antigen–Negative Chronic Hepatitis B: A Multicenter Real-World Study. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf198
Vancouver
Chen J, Huang Z, Yang X, Yang Y, Tan M, Duan L, et al. Predictors of Durable Hepatitis B Surface Antigen Loss After Pegylated Interferon–Based Therapy in Patients with Hepatitis B e Antigen–Negative Chronic Hepatitis B: A Multicenter Real-World Study. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiaf198
BibTeX
@article{Chen2025,
author = {Chen, Jun and Huang, Zebing and Yang, Xueyao and Yang, Yongwen and Tan, Min and Duan, Lihua and Li, Xuexuan and Gao, Shang and Gao, Zhiliang and Huang, Yan},
title = {Predictors of Durable Hepatitis B Surface Antigen Loss After Pegylated Interferon–Based Therapy in Patients with Hepatitis B e Antigen–Negative Chronic Hepatitis B: A Multicenter Real-World Study},
journal = {The Journal of Infectious Diseases},
year = {2025},
doi = {10.1093/infdis/jiaf198}
}
EUVIMED